检索临床试验

这项临床试验的目的是测试CPO301, a type of drug called an antibody drug conjugate in adult patients with 先进的 or metastatic solid tumors.

它旨在回答的主要问题是:

• 评估CPO301增加剂量的安全性和耐受性，并确定研究第二部分(A部分)的使用剂量。
• 在A部分中确定的剂量下，评估CPO301在非小细胞肺癌和其他潜在肿瘤类型患者中的安全性和耐受性(B部分)。
• To evaluate how quickly CPO301 is metabolized by the body (药物动力学 or PK)
• To evaluate if antibodies to the study drug develop (immunogenicity)
• 评价药物的初步疗效
• To correlate preliminary 功效 with mutations in a biomarker called EGFR

参与者将:

• 提供书面知情同意
• Undergo screening tests to ensure they are eligible for study treatment
• 参加所有要求的研究访问，每3周静脉注射一次CPO301，直到研究医生确定应该停止研究治疗, 基于参与者在治疗中的表现
• Be followed for progression every 3 months for up to 2 years

本研究的主要目的是评估E7386的安全性和耐受性，并确定E7386与其他抗癌药物联合的推荐2期剂量(RP2D)。.

这是第一次人体试验, 阶段1 b / 1, 多中心, 非盲, STK-012在选定的晚期实体瘤患者中作为单药和联合派姆单抗的剂量递增研究.

一个first-in-human, 非盲, 多中心, Phase 1 study of KZR-261 designed to assess the safety and 耐受性, 初步抗肿瘤活性, KZR-261的药代动力学(PK), as well as identify the recommended Phase 2 dose (RP2D). The study comprises a Part 1 (Dose Escalation) and a Part 2 (Dose Expansion) in solid organ tumors (melanoma/uveal melanoma, 间皮瘤, 结肠直肠癌, 前列腺癌, 和“肿瘤”).

本研究旨在确定其安全性, 药物动力学(PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, 还有安全性, 功效, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, 先进的, 分化良好型的, 生长抑素受体表达(SSTR+)的胃肠胰神经内分泌肿瘤(GEP-NETs)在接受Lutetium 177标记的生长抑素类似物(177Lu-SSA)治疗后进展, such as 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu-DOTATATE/TOC), 或177lu -高亲和力[HA]-DOTATATE.

这项研究将评估安全性, 耐受性, 药物动力学(PK), 药效学(PD), 在490例复发/进展的晚期癌症患者中，AZD9574单独和联合抗癌药物的初步疗效.

This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 (mirdametinib) combination in participants with tumors.

这是一项1/2期研究，旨在评估ARX517作为单一疗法或联合疗法在患有转移性去雄抵抗性前列腺癌(mCRPC)的成人受试者中的安全性和耐受性.

这项首次人体研究将评估安全性, 耐受性, 药物动力学, and antitumor activity of UCT-01-097 in patients with 先进的 solid tumors.

这是第一阶段, 非盲, 随访时间, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid tumors.

RSC-101是RSC-1255在成人研究参与者中进行的一项1a/1b期临床试验，这些参与者患有晚期实体肿瘤恶性肿瘤，对现有已知的临床益处治疗不耐受, have disease that has progressed after standard therapy, 或者之前其他治疗失败. 这项研究分为两个阶段. 1a期(剂量递增)的目的是确定适当的治疗剂量，1b期(剂量扩展)的目的是表征RSC-1255的安全性和有效性.

1/2期开放标签, 安全性的多中心研究, 药物动力学, LYT-200单独和联合化疗或Tislelizumab在转移性实体瘤患者中的抗肿瘤活性

该II期试验研究abemaciclib在治疗具有CDK4/6通路激活且复发(复发)的卵巢癌或子宫内膜癌患者方面的效果如何. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving abemaciclib may work better for the treatment of recurrent ovarian and endometrial cancer.

本探索性研究探讨了一种名为68Ga-FAPi-46 PET/CT的成像技术如何确定FAPI示踪剂(68Ga-FAPi-46)在癌症患者的正常和癌组织中积聚的位置和程度. Because some cancers take up 68Ga-FAPi-46 it can be seen with PET. FAP代表成纤维细胞活化蛋白. FAP is produced by cells that surround tumors (cancer associated fibroblasts). The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers.

评估研究方案中对KRAS成人患者使用索托拉西布的安全性和耐受性.G12C突变体晚期实体瘤.

Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab.

Part 2 is phase II design of APG-115 at recommended phase 2 dose (RP2D) in combination with pembrolizumab.

第一阶段将评估不同剂量水平的repotrectinib在患有晚期或转移性淋巴瘤激酶(ALK)的儿童和年轻成人患者中的安全性和耐受性。, receptor tyrosine kinase encoded by the gene ROS1 (ROS1), 或神经营养受体激酶基因编码TRK激酶家族(NTRK1-3)的改变来估计最大耐受剂量(MTD)或最大给药剂量(MAD)并选择儿科推荐的2期剂量(RP2D)。.

二期试验将确定repotrectinib在ROS1或NTRK1-3改变的晚期或转移性恶性肿瘤的儿童和青年患者中的抗肿瘤活性.

在这项观察性研究中，研究人员希望更多地了解药物VITRAKVI(通用名称:larorectinib)的有效性，以及该药物在TRK融合癌患者常规使用期间的耐受性如何，这些患者局部进展或从其开始的地方扩散到身体的其他部位. TRK融合癌是一个术语，用于描述由NTRK(神经营养酪氨酸激酶)基因的变化引起的各种常见和罕见的癌症，称为融合. During this fusion, an NTRK gene joins together, or fuses, with a different gene. This joining results in the activation of certain proteins (TRK fusion proteins), which can cause cancer cells to multiply and form a tumor. VITRAKVI is an approved drug that blocks the action of the NTRK gene fusion. 该研究将招募患有NTRK基因融合实体瘤的成人和儿童患者，他们的治疗医生已经决定用VITRAKVI治疗他们的疾病. 研究期间, patients' medical information such as treatment information with VITRAKVI, 其他药物或治疗, 疾病状况和其他健康体征和症状的变化将由治疗医生在正常医疗护理范围内收集. Participants will be observed over a period from 24 to 60 months.